Genetic risk factors and COVID-19 severity in Brazil: results from BRACOVID study

Carregando...
Imagem de Miniatura
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Citação
HUMAN MOLECULAR GENETICS, v.31, n.18, p.3021-3031, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The coronavirus disease 2019 (COVID-19) pandemic has changed the paradigms for disease surveillance and rapid deployment of scientific-based evidence for understanding disease biology, susceptibility and treatment. We have organized a large-scale genome-wide association study (GWAS) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals in Sao Paulo, Brazil, one of the most affected areas of the pandemic in the country, itself one of the most affected in the world. Here, we present the results of the initial analysis in the first 5233 participants of the BRACOVID study. We have conducted a GWAS for COVID-19 hospitalization enrolling 3533 cases (hospitalized COVID-19 participants) and 1700 controls (non-hospitalized COVID-19 participants). Models were adjusted by age, sex and the 4 first principal components. A meta-analysis was also conducted merging BRACOVID hospitalization data with the Human Genetic Initiative (HGI) Consortia results. BRACOVID results validated most loci previously identified in the HGI meta-analysis. In addition, no significant heterogeneity according to ancestral group within the Brazilian population was observed for the two most important COVID-19 severity associated loci: 3p21.31 and Chr21 near IFNAR2. Using only data provided by BRACOVID, a new genome-wide significant locus was identified on Chr1 near the genes DSTYK and RBBP5. The associated haplotype has also been previously associated with a number of blood cell related traits and might play a role in modulating the immune response in COVID-19 cases.
Palavras-chave
Referências
  1. Allain-Dupr? D., 2020, TERRITORIAL IMPACT C
  2. Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
  3. [Anonymous], 2021, COVID 19 DASHBOARD C
  4. Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
  5. Boughton AP, 2021, BIOINFORMATICS, V37, P3017, DOI 10.1093/bioinformatics/btab186
  6. Casanova JL, 2020, HUM GENET, V139, P681, DOI 10.1007/s00439-020-02184-w
  7. Casanova JL, 2021, ANNU REV PATHOL-MECH, V16, P23, DOI 10.1146/annurev-pathol-031920-101429
  8. Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
  9. D'Antonio M, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.110020
  10. Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
  11. Feng HL, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1008973
  12. Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
  13. Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
  14. Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
  15. Li YF, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00318-6
  16. Morens DM, 2020, CELL, V182, P1077, DOI 10.1016/j.cell.2020.08.021
  17. Nakanishi T, 2021, J CLIN INVEST, V131, DOI [10.1172/JCI152386, 10.1101/2021.03.07.21252875]
  18. Ovsyannikova IG, 2020, IMMUNOL REV, V296, P205, DOI 10.1111/imr.12897
  19. Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y
  20. Preparation S, 2018, NO DP AXIOM TM 2 0 G
  21. van Blokland IV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255402
  22. Weinstein M., 2020, NEW ENGL J MED, V362, P567
  23. Zeberg H, 2020, NATURE, V587, P610, DOI 10.1038/s41586-020-2818-3
  24. Zhu JJ, 2021, J INFECT DIS, V223, P19, DOI 10.1093/infdis/jiaa660
  25. Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017